News
Atraverse Medical has raised $29.4 million to fund its minimally invasive system for accessing the inner chambers of the ...
Bristol Myers Squibb didn’t want to choose between clinical expertise and financial know-how when selecting a new leader. | ...
Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...
Once hailed as the future of immuno-oncology, it’s been a tough few months for any remaining fans of anti-TIGIT antibodies. | ...
Every year, the Fierce Medtech team highlights 15 standout companies that are pushing the boundaries of innovation in medical ...
After 25 years developing vaccines with French drugmaker Sanofi, Sanjay Gurunathan, M.D., has departed for GSK. Gurunathan ...
AstraZeneca has returned to recent licensing partner CSPC Pharmaceuticals with $110 million in upfront cash to start work on ...
The offer is the result of a memorandum of understanding signed by both Astellas and Japanese think tank Mitsubishi Research ...
Exoskeleton developer Wandercraft has raised $75 million in new financing shortly after inking a strategic partnership with ...
ADC Therapeutics shutters UK R&D site, culls several preclinical programs and trims workforce by 30%
After dropping its only clinical-stage candidate last month, ADC Therapeutics is shutting down a U.K. research site and ...
GSK has licensed its shigella vaccine candidate to Bharat Biotech. The Big Pharma, which has vowed to help Bharat with trial ...
BioNTech is buying fellow German mRNA vaccine developer CureVac in an all-stock transaction that values the acquired biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results